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1. Introduction 
External ocular infections caused by adenoviruses are among the most common eye infections 
seen worldwide. They lead to highly infectious community epidemics, seasonal outbreaks, lost 
productivity, significant patient discomfort and in some cases permanent visual compromise 
from long-term immune-mediated sequelae1. Though several therapeutic agents have been 
evaluated for acute viral conjunctivitis in both animal models and human trials, none to date 
have been approved for therapeutic use in humans2,3,4. Both bacterial and viral pathogens 
cause acute infectious diseases of the ocular surface with similar clinical presentation. Key 
differences exist in the mechanism, host response and epidemiology of each etiologic agent. 
Consideration of these differences shapes our approach to treatment and our approach to the 
evaluation of therapeutic agents in clinical trials. 
2. Clinical features of bacterial and adenoviral conjunctivitis 
All acute conjunctivities share some common clinical features that aid in the design of 
appropriate clinical evaluations. Most cases involve conjunctival hyperemia with varying 
chemosis, some component of ocular discharge and a constellation of symptoms that can 
include foreign body sensation, pain and itching. A recent evidence-based review5 examined 
several databases, including the Cochrane Controlled Trials Register, along with standard 
ophthalmology texts and concluded that signs and symptoms of acute bacterial and acute 
viral conjunctivitis are essentially identical. Measurement of the resolution of these 
symptoms is an essential part of the clinical evaluation of agents for use in acute 
conjunctivitis of any etiology. Analogy can be made with bacterial conjunctivitis for the 
clinical signs and symptoms of viral infection, and this analogy can guide in the selection of 
clinical endpoints. For this reason, the use of similar clinical criteria for one of the primary 
efficacy endpoints in both viral and bacterial clinical trials is suggested. 
3. Differences in bacterial and adenoviral relationship to the healthy ocular 
surface 
Bacterial conjunctivitis is commonly caused by normal ocular surface flora6. When the 
balance between host defense and microbial colonization on the ocular surface is somehow 
disrupted, the commensal relationship can proceed to frank infection7. Key factors that 
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affect this pathogenic conversion appear to be related both to host defense compromise and 
specific bacterial species present8. 
In contradistinction to bacteria, adenovirus species are not typically found among the 
normal ocular flora9,10,11. A definitive study employing tissue culture in ocular swab samples 
obtained from the conjuntival fornicies was unable to demonstrate the presence of 
adenovirus from even a single sample of over 200 collected in asyptomatic patients 
presenting for routine eye exam12. The absence of adenoviral colonization was similarly 
demonstrated in conjunctival specimens studied by tissue culture obtained from a series of 
patients with symptoms of non-infectious keratoconjunctivitis sicca13. The presence of 
adenovirus on the ocular surface would seem to indicate active or recent convalescent 
infection. This is a critical difference between bacterial and adenoviral conjunctivitis and 
must be considered when selecting efficacy endpoints for the evaluation of therapeutic 
agents. Anti-bacterials can clearly demonstrate their clinical utility by simply showing the 
resolution of clinical signs and symptoms in a shorter time period than would be expected 
with non-intervention. There is no need to show elimination of bacterial colonization as 
bacterial sterility is not a feature of the healthy ocular surface. Bacterial conjunctivitis is a 
much rarer cause of community outbreaks and is less likely to be associated with person-to-
person transmission. Described below is the very different behavior of viral conjunctivitis 
and the relationship between transmissibility and viral shedding. 
4. Viral transmission and shedding 
The differences in the transmissibility of bacterial and viral conjunctivitities merit careful 
consideration. Ocular adenoviral infection represents a significant  public health problem in 
the US and worldwide14, 15 Although exact numbers are difficult to determine, estimates 
from a US survey of outpatient health encounters4,9, comparison with epidemiological 
surveys completed in outside the US15 and studies of incidence in military recruits16 suggest 
that the number of cases of viral conjunctivitis may be as high as 15-20 million per year in 
the United States. Adenovirus conjunctivitis is a reportable infection in Germany17 and is 
classified as a Category IV infectious disease by Japan’s National Epidemiological 
Surveillance of Infectious Diseases (NESID) with mandated collection, analysis and 
publication of reports on occurrences18. 
Adenoviral transmission between infected and uninfected hosts is particularly efficient in 
areas of high population density, overcrowding or poor hygiene19. Studies on the rate of20 
horizontal transmission to asymptomatic family members and close contacts suggest 
transmissibility of up to 50%21,22,23. Adenovirus is spread through droplets from the 
respiratory tract, stool, saliva and tears. Through a process known as viral shedding, 
infectious particles are transferred from the extracellular environment of lytic infected cells 
through a variety of fomites24. Adenoviral particles, presumably shed from infected patients, 
have been isolated from multi-dose ophthalmic medications and diagnostic solutions25,26 
Recovery of infectious adenovirus has been reported from samples obtained from inanimate 
hard surfaces and objects for up to 49 days27,28. Actively infected persons readily transmit 
adenoviruses. Viral shedding persists for 12-14 days after onset of clinical signs and 
symptoms. Transmission can be prevented by personal hygiene measures including 
frequent handwashing; cleaning of towels, pillowcases and handkerchiefs; and disposal of 
contaminated facial tissues. Patients with adenoviral conjunctivitis may shed virus to these 
objects which can in turn infect other hosts Individuals who work with the public, in 
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schools, or in healthcare facilities in particular should consider a temporary leave of absence 
from work to prevent infection of others, especially those who are already ill29. This is 
common in hospital and clinic settings and can lead to systemic disease with or without 
conjunctivitis, particularly in immunocompromised patients30. The most effective measures 
for limiting the severity of adenoviral conjunctivitis outbreaks rely on reducing the 
contamination of objects, workspaces and surfaces by aggressive steps to remove shed virus 
particles31,32. It follows that reducing shedding at the source - the infected ocular surface- 
would be a highly effective strategy for epidemic prevention and control. 
The clear relationship between shedding virus and infectivity necessarily affects our 
therapeutic options and our therapeutic requirements in acute viral conjunctivitis. The 
additional burden is placed on the evaluation of anti-adenoviral agents given their 
devastating potential to cause outbreaks. Proposed therapeutic agents should aim for a 
reduction in viral shedding in addition to the resolution of clinical symptoms. An 
evaluation of efficacy that incorporates both reduced viral infectivity and improvement in 
symptoms is required to fully demonstrate the utility of any proposed anti-adenoviral 
therapeutic agent. 
Similar patterns of epidemic spread, droplet transmission and shedding are not typical 
features of bacterial conjunctivitis, though outbreaks have been reported in humans33 and 
vector-dependent spread confirmed in animal models34,35,36. Bacterial conjunctivitis is a 
much less likely cause of outbreaks and is not a significant public health challenge (we 
acknowledge the enormous importance of bacterial conjunctivitis caused by C. Trachoma and 
defer its discussion as it is more commonly a chronic, endemic, recurrent infection with a 
distinct clinical course)37. Though vertical transmission remains an important aspect of 
neonatal bacterial conjunctivitis, these cases are rare in the industrialized world and do not 
share the features of epidemic infection. Furthermore neonatal conjunctivitis passed intra-
partum from mother to newborn is easily eliminated through ocular administration of 
povidone-iodine at the time of birth38. 
5. Ocular immune response in bacterial and adenoviral infections 
Components of both the innate and adaptive acquired immune systems play important 
roles in ocular defense.39 While the predominantly extracellular bacterial pathogens are 
more effectively controlled by the innate ocular defense mechanisms, viral infections often 
lead to a more prolonged course. Viral exposures frequently involve a more robust 
acquired immune cascade with significant inflammatory damage4041,42. It is precisely this 
exuberant immune reaction that leads to the signs and symptoms of viral conjunctivitis 
and immune-mediated sequelae. It is often clinically beneficial to temper the ocular 
immune response in both viral and bacterial infections, with topical steroids frequently 
the agents of choice. Steroids have well characterized effects on both innate and adaptive 
immunity. The features of the immune responses to viral and bacterial pathogens need to 
be considered along with the relative effects of steroid on each system: Steroids have a 
more dramatic inhibitory effect on the adaptive system, and this is precisely the system 
that is most important at eliminating viral infections. In expected that steroids would have 
less of an effect on the eye’s ability to counter bacterial pathogens than they would on the 
elimination of viral organisms. It has been demonstrated that co-administration of potent 
topical steroids along with antibiotics does not lead to higher bacterial counts (measured 
as CFU’s)43 in the normal bacterial conjunctival flora. 
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It has been repeatedly shown in ocular adenoviral infection that use of topical steroids can 
prolong the duration of viral shedding and therefore lengthen the period of transmissibility 
in these cases44. It is for this reason that topical steroid monotherapy in ocular adenovirus 
infections is ill-advised. It is well known that a short course of topical corticosteroids (and in 
some severe cases oral steroids) can limit patient discomfort and prevent some immune-
related inflammatory complications of acute viral conjunctivitis. While this strategy may 
have some efficacy in the short-term amelioration of symptoms, even a short course of 
relatively low-potency corticosteroids without the addition of a suitable anti-viral agent can 
increase the duration of viral shedding and prolong the infectivity of affected patients45. The 
addition of topical steroids cripples the eye’s immune response to viral pathogens. The 
effect on the ability to effectively clear viral infections is so pronounced that the addition of 
topical steroids can even reverse the effect of the most potent anti-virals46. This in turn can 
potentiate the occurrence of community outbreaks and epidemic transmission in schools, 
places of business and medical facilities47. As described above, this additionally requires that 
effects on infectivity be considered along with symptom resolution in the clinical evaluation 
of anti-adenoviral therapies48. 
6. Detection of adenoviral infectivity 
There are several techniques available for the detection of adenovirus from ocular 
specimens. Despite recent advances in nucleic acid-based detection and the availability of a 
rapid point-of-care immunochromatographic tests for the presence of specific viral 
components, cell culture remains the only reliable method for the demonstration of viable, 
infectious virus. 
Cell culture with confirmatory immunofluorescence (CC-IFA) is a highly sensitive and 
specific test and is considered the “gold standard” for the recovery of infectious virus from 
ocular samples. CC-IFA requires the presence of infectious virus and demonstrates 
unequivocally the ability of the recovered virus to cause a cytopathic effect (CPE) in a living 
cell. When combined with immunoflourescent staining, it provides a means to determine 
the presence, infectivity and identity of a viral specimen. 
A sample from a conjunctival swab is inoculated in susceptible cell line and followed over 
time to measure the cytopathic effects (CPE). The “Shell Vial Culture” method is a specific 
cell culture technique that enables more rapid identification of CPE49. This test utilizes shell 
vials, centrifugation and visualization of adenovirus proteins inside host cells through 
binding of fluorescent dye. Shell vials are glass culture tubes that contain a coverslip coated 
with an A549 cell monolayer. The culture tube is inoculated with the clinical specimen and 
the tube is centrifuged at low speed and incubated. It is hypothesized that the centrifugation 
enhances the adenoviral entry into the susceptible cells. The visualization technique is 
indirect, where a secondary antibody labeled with fluorochrome is used to recognize a 
primary antibody directed towards a conserved adenoviral epitope. This test significantly 
shortens the time requirement and enhances the sensitivity and specificity. Positive results 
can be obtained from the visualization of even a single brightly stained cell, confirming that 
the adenoviral particles were capable of entering a cell, uncoating, replicating and 
producing infectious prodigy virions. In this way CC-IFA in general and the Shell Vial 
method specifically provide an unequivocal way to determine the infectivity of an ocular 
specimen. It is for this reason that we propose assessment of infectivity by CC-IFA as a 
second primary endpoint for clinical trials designed to evaluate the efficacy of anti-
adenoviral therapeutic agents. 
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Tobramycin (AK_Tob, Tobrex) 
Gentamycin (Gentak, Gentasol) 
Moxifloxacin (Vigamox) 
Polymyxin B and trimethoprim (Polytrim) 
Bacitracin (Ak-Tracin, Bacitcin) 
Ofloxacin (Ocuflox) 
Sulfacetamide (Cetamide, Ocusulf_10) 
 
Combination Antibiotic-Steroid Drugs 
Tobramycin and dexamethasone (Tbradex) 
betamethasone and neomycin 
dexamethasone and neomycin/ polymixin B (Maxitrol) 
Loteprednol / tobramycin (Zylet) 
Prednisolone/polymyxin B/neomycin (PolyPred) 
Prednisolone/gentamycin (PredG) 
Prednisolone / sulfacetamide (Blephamide) 
 
Though all of the above are commonly used to treat viral and bacterial conjunctivitis, none are 
approved by the FDA for use in acute viral conjunctivitis. 
Table 1. Drugs commonly used to treat acute conjunctivitis 
7. Proposed clinial study design for demonstrating utility of therapeutic 
agents in acute adenoviral conjunctivitis 
The ideal treatment for adenoviral conjunctivitis would alleviate patient symptoms, 
resolve clinical signs, decrease inflammatory damage, shorten the clinical course of 
infection, reduce the duration of viral shedding and decrease the period of infectivity. The 
evaluation of all therapeutic agents for use in adenoviral conjunctivitis should include 
analysis of clinical and infectious parameters and consider effects on the individual 
patient and the community as a whole. The use of separate primary efficacy endpoints is 
proposed that can demonstrate the following: 
1. Resolution of signs and symptoms associated with viral conjunctivitis. 
2. Decrease in infectious viral shedding measured by CC-IFA at the test-of-cure visit. 
Resolution of signs and symptoms of the disease is the most clinically meaningful 
assessment and derives from the similar clinical features shared by acute bacterial and acute 
viral conjunctivitis. Particularly from the patient’s individual perspective, the resolution of 
signs and symptoms is the most important clinical outcome. Much can be learned and 
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borrowed from the myriad experience gained over decades of clinical trials in bacterial 
conjunctivitis. The use of standardized conjunctivial grading, scaled scoring for ocular 
discharge and conjunctival injection all have application in both bacterial and viral disease. 
The required analysis of viral shedding, which derives from the differences in transmission 
between bacterial and viral conjunctivitis, is important to ensure that symptomatic relief in 
individuals doesn’t lead to prolonged infectivity. The ideal therapeutic will radpidly decrease 
viral loads and shorten the overall length of time that active, replicating virus can be isolated 
from the ocular surface. This will ensure that the simple masking of symptoms cannot be 
substituted for a true viral cure. Though indivdual subjects may improve on symptom-
alleviating therapy only, the requirement to reduce infectivity should ensure that no agents 
gain approval that could potentially lengthen epidemics or threaten the public health. 
The requirement for all proposed agents to satisfy both of these endpoints is the most 
effective way to ensure that proposed ant-adenoviral therapies address both the infectious 
and inflammatory consequences of the disease. 
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